Suchergebnisse

Cover -- Title -- Copyright -- Contents -- WHO Expert Committee on Drug Dependence -- Abbreviations -- Introduction -- 1. Work of international bodies concerned with controlled substances -- 1.1 Update from the International Narcotics Control Board -- 1.2 Update from the United Nations Office on Drugs and Crime -- 1.3 Update from Management of Substance Abuse Unit, WHO -- 1.4 Update from Essential Medicines and Health Products, WHO -- 2. Criteria for assessing new psychoactive substances -- 3. Terminology -- 4. Follow-up on recommendations made by the ECDD at its thirty-sixth meeting -- 4.1 Mephedrone -- 4.2 Ketamine (INN) -- 4.3 AH-7921 -- 4.4 Gamma-butyrolactone (GBL) -- 4.5 1,4-Butanediol (1,4-BD) -- 4.6 25B-NBOMe -- 4.7 25C-NBOMe -- 4.8 25I-NBOMe -- 4.9 N-Benzylpiperazine (BZP) -- 4.10 JWH-018 -- 4.11 AM-2201 -- 4.12 3,4-Methylenedioxypyrovalerone (MDPV) -- 4.13 Methylone (BK-MDMA) -- 5. Critical review of psychoactive substances -- 5.1 MT-45 -- 5.2 Acetylfentanyl -- 5.3 α-Pyrrolidinovalerophenone (?-PVP) -- 5.4 4-Fluoroamphetamine (4-FA) -- 5.5 para-Methyl-4-methylaminorex (4,4'-DMAR) -- 5.6 para-Methoxymethylamphetamine (PMMA) -- 5.7 Methoxetamine (MXE) -- 6. Pre-review of psychoactive substances -- 6.1 Etizolam (INN) -- 6.2 Phenazepam -- 7. Updates -- 7.1 Ketamine (INN) -- 7.2 Cannabis and cannabis resin -- 8. Future agenda items -- Acknowledgements -- References.